This prospective observational study explored the efficacy and tolerability of levetiracetam (LEV) in a prospective series of 200 patients with refractory epilepsy attending a single epilepsy service. Patients were started on adjunctive LEV using one of two titration schedules (slow and fast) and patients were studied for at least 6 months after commencing LEV. Fifty-three patients had severe learning disabilities. 14.3% became seizure free, 57.7% showed >50% reduction, 15.4% showed seizure increase. Patients with learning disability showed less positive but still very worthwhile results. A highly significant improvement in clinical outcomes overall is shown (P < 0.0001). 56.6% showed no adverse effects, 27.4% showed minor adverse effects, 16% were withdrawn. The most common adverse effect causing drug withdrawal was seizure exacerbation (12%) which was much commoner in primary generalised epilepsies (P = 0.00035). LEV appears to be an effective and well-tolerated anti-epileptic drug in drug resistant partial epilepsies.
INTRODUCTION
The new anti-epileptic drug levetiracetam (LEV) has an unknown mechanism of action but has demonstrated novel anti-epileptic activity in various animal models 1, 2 . The effectiveness of this drug as adjunctive anti-epileptic therapy has been established in three multicentre, well-controlled phase III studies in patients with a history of partial-onset seizures, with or without secondary generalisation [3] [4] [5] . The pooled data has been reviewed and has demonstrated consistent anti-seizure activity in this group of patients 6 . Safety data from these trials had been reviewed by Harden 7 . Long-term continuation of LEV has been demonstrated in a continuation study 8 , suggesting a retention rate of 60% after 1 year and 32% after 5 years. In that review 13% of patients became seizure-free for at least 6 months.
LEV has therefore been shown to have proven efficacy as add-on therapy in partial-onset seizures and there is some evidence for its efficacy in primary generalised seizures 9, 10 .
Whilst randomised placebo-controlled, fixed-dose clinical trials are essential to establish the efficacy and tolerability of a new AED, such studies may be of relatively limited relevance in the practical use of a new drug in everyday clinical practice. The current prospective observational study, carried out in a specialist epilepsy centre, aims to demonstrate and explore the use of LEV in a population of patients with refractory epilepsy, many of whom also had significant learning disabilities.
METHOD
Prospective data were analysed in a consecutive series of all patients started on LEV at the Burden Centre for Neuropsychiatry, Neuropsychology and Epileptology during the first year after the drug was licensed. This population of patients all had refractory epilepsy and had all been treated previously with multiple AEDs (mean of 2.3 for primary generalised and 4.6 for localisation related epilepsies). All patients remained on alternative AEDs at the start of the study and all patients had continued to have seizures for more than 2 years in spite of treatment with a range of AEDs. One hundred and seventy-five patients were studied prospectively, all of whom were studied for 6 or more months after starting LEV therapy. The age range of patients was from 15 to 73 years (median 42 years) and the length of history of epilepsy was recorded as being between 2 and 51 years (median 12 years). Data were obtained on 200 patients but efficacy data have not been analysed on 25 patients who were on LEV for less than 6 months at the time of analysis. Of the 175 patients studied, 92 were male and 83 were female. Twenty-two patients (12.6%) had primary generalised epilepsy whilst 153 (87.4%) had partial seizures with or without generalisation.
Patients were asked to document their seizures for at least 3 months before starting on LEV and maintained on an unchanged dosage of previous AEDs for that period. Patients were taking a mean of 2.2 other AEDs at the onset of LEV treatment.
LEV dosage was titrated at two different rates. Build-up to 3000 mg daily over a period of 6 weeks was regarded as 'fast rate' and build-up to 2000 mg daily over 8 weeks was regarded as a 'slow rate'. Initially 'fast rate' was used, then it was decided to change to 'slow rate' after the first 6 months of the study. Sixty-four patients (37%) underwent fast rate titration whilst 111 patients (63%) underwent slow rate titration. If the patient was seizure-free on either the 2000 mg/day dose or the 3000 mg/day dose, then no alteration in the regime was made unless further seizures occurred. Wherever possible, concomitant AEDs were withdrawn. Patients were seen every 8-12 weeks by one or other of three senior clinicians.
At each visit the patient's seizure chart was checked and any adverse effects were documented. Discontinuation of LEV was undertaken if there was the development of unacceptable side effects, exacerbation of epilepsy or lack of efficacy.
Fifty-three (30.3%) of the overall population of patients had severe or profound learning disabilities.
RESULTS

Efficacy
Overall, 25 (14.3%) of the 175 patients became seizure-free for at least 6 months. A further 101 patients (57.7%) showed a greater than 50% reduction in seizure frequency for at least a 6-month period whilst 28 patients (16%) showed no significant change and 21 (15.4%) showed a significant increase in seizure frequency. During the study period (6-20 months), the longest period of seizure freedom was 19 months and 15 patients attained seizure freedom for more than 12 months. These results show a highly significant improvement when comparing pre LEV treatment condition with condition on LEV (P < 0.0001).
The length of history of epilepsy was assessed and was not related to the likelihood of seizure freedom with LEV.
No significant relationship was found between seizure freedom with LEV and any particular additional AED taken, but sample sizes are small for each individual drug. Similarly, no particular combination of AEDs with LEV was found to result in a significant increase in adverse effects.
The relationship between seizure freedom and either primary generalised-or localisation-related seizures was assessed, four patients (18%) with primary generalised seizures became completely seizure-free for more than 6 months whilst 21 patients (13.7%) with localisation-related epilepsy became seizure free for more than 6 months. This is not a significant difference. It must be born in mind that this was a particularly treatment resistant group, many with multiple problems in addition to epilepsy.
Of the 53 patients with severe or profound learning disabilities, 7.6% showed complete seizure freedom whilst 69.8% showed a greater than 50% seizure reduction. This compared with the population without learning disability, of whom 17.2% showed complete seizure freedom whilst 52.6% showed greater than 50% seizure reduction. Figures for increased seizure frequency were about the same (learning disabled population-11.3%, non learning disabled population-12.3%).
At the end of the study period, 12 patients (6.8%) were settled on mono therapy with LEV, three showing complete seizure cessation, five showing more than 90% reduction in seizure frequency and four showing greater than 50% reduction in seizure frequency, two of whom commented that their seizures were much less intense.
Adverse effects
Adverse effects were assessed according to a 3-point scale, 0 meaning no adverse effects experienced, −1 referring to minor adverse effects but continuing with treatment and −2 referring to adverse effects resulting in treatment withdrawal.
Ninety-nine patients (56.6%) experienced no adverse effects, 48 (27.4%) experienced minor adverse effects but continued with treatment and 28 patients (16%) were withdrawn either because of adverse effects or, more commonly, due to lack of efficacy or exacerbation of seizure frequency. Twenty-one patients (12%) were withdrawn primarily due to increase in seizure frequency or a combination of this with other adverse effects. Two patients showed the development of psychosis, at a late stage after 6 months of complete or near seizure freedom. The most common adverse effect other than seizure exacerbation to result in drug withdrawal was the development of aggression, all seven such patients were learning disabled and in five of these there was associated seizure frequency increase whilst in one there had been seizure cessation.
Adverse effects are noted in Table 1 . Significantly more patients with primary generalised seizures were withdrawn due to adverse effects, including seizure exacerbation. (45.45% primary generalised cf. 11.76% partial, Fisher's exact probability = 0.00035.)
Patients with 'fast rate' titration (0-3000 mg/day within 6 weeks) were compared with 'slow rate' dose titration (0-2000 mg/day over 8 weeks). Those who completed these schedules did not show any difference in overall efficacy or in frequency or severity of adverse effects. Thus, on the one hand, slower build-up of medication did not appear to reduce the likelihood of the development of adverse effects, on the other hand 2000 mg/day, in this study, seems as effective for most patients as is 3000 mg/day. Six patients did so well that they did not need to build up to 2000 mg/day, two patients have remained seizure-free for more than 12 months on 500 mg/day and a further two patients have remained seizure-free for more than 12 months on 1000 mg/day. These patients were all in the 'slow rate' titration group.
DISCUSSION
This study has demonstrated continued efficacy of LEV in a population of patients with refractory epilepsy who are being treated in an epilepsy clinic rather than in a research setting. The expected differences in efficacy of LEV in populations with and without learning disability has been demonstrated, patients without learning disability have shown a 17.2% seizure freedom rate for more than 6 months whilst those with learning disability have shown a 7.6% seizure freedom rate. Nevertheless, even in the population with learning disabilities, almost 70% have shown a greater than 50% reduction in seizure frequency. Adverse effect profiles have demonstrated greater likelihood of adverse effects in those with primary generalised seizures but not particularly in those with learning disabilities. However, aggression was seen more commonly as an adverse effect in the learning disabled group. Whilst there have been significant numbers of patients with primary generalised epilepsy who have responded well to LEV, there has been a significantly greater number who have shown seizure exacerbation than in the population with localisation-related epilepsy.
Smith et al. 10 have reported marked efficacy in Juvenile Myoclonic Epilepsy, however, in our group two of six patients with this condition showed early and very marked exacerbation of myoclonus, one showing his first tonic-clonic seizure for 5 years (without any concomitant drug reduction). All the others did well and were being seizure-free for 6 or more months.
In 85 patients (48.6%) concomitant AEDs were withdrawn, with 12 patients being on LEV monotherapy at the close of the study. In the majority of cases LEV replaced another AED, whilst in 28 patients more than one AED was withdrawn during the 20-month study period.
CONCLUSION
LEV has been shown, in this population of 200 patients with refractory epilepsy, to be an effective, safe and important addition to the anti-epileptic armamentarium. All patients in this study had been previously treated with a wide range of AEDs, without success-hence to achieve 14.3% seizure freedom (17.2% in the non learning disabled group) is remarkable. To do so with only 16% withdrawal due to adverse effects makes the drug still more useful in clinical practice. As with other AEDs seizure relief can, rarely, be associated with the development of psychosis. Exacerbation of seizures appears to be the most common serious adverse effect, especially in the primary generalised group-but this group may also do very well in some cases. In the learning disabled group aggressive behaviour change is relatively common.
LEV appears, in clinical practice, to be an important new AED with a broad spectrum of activity.
